Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025

Cartesian Therapeutics, Inc.

Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.
Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.
Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.
CFO Blaine Davis continues as both principal financial officer and principal accounting officer.
Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000104
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-10-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.443798+00:00
generated_at: 2026-05-17T04:18:27.359520+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.4
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000104
json_url: https://secwatch.observer/filing/0001453687-25-000104.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000104.md
text_url: https://secwatch.observer/filing/0001453687-25-000104.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/0001453687-25-000104-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/rnac-20251002.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000104

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.